Lifecore Biomedical, Inc. Common Stock (LFCR)
Score for how it compares with the broader market is near the top of its range; short-term momentum is one of its highest-scoring factors; and business numbers score is on the low side.
LFCR scores higher than 90% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Lifecore Biomedical, Inc. Common Stock (LFCR) scores 64 out of 100 on the Market Census six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.80× 30-day average
- 52-week range
- 3.62 – 8.98
- Market cap
- $168.82M
- Earnings date
- —
- Volume
- 387,101
- Avg. volume (30d)
- 486,245
- Open
- 6.43
- Previous close
- 6.43
- Day's range (regular session)
- 6.42 – 6.46
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 1.08
- P/E (TTM)
- —
- EPS (TTM)
- -1.31
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about LFCR right now
Lifecore Biomedical, Inc. Common Stock (LFCR) currently scores 64/100 on the Market Census six-factor composite, at the Above average score level. LFCR is +0.31% on the day and -1.45% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for LFCR leans good, with some weak spots. LFCR's strongest factor is strength vs the market at 100/100 — a very strong read on how LFCR has done next to the wider market. It describes what has happened, not what happens next. The weakest factor is company finances at 7/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See LFCR in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent LFCR news
Latest headlines that name Lifecore Biomedical, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Lifecore Biomedical to Participate at Upcoming Industry ConferencesYahoo
- Halper Sadeh LLC is Investigating Whether MG, LFCR, MGLD are Obtaining Fair Deals for their ShareholdersGlobeNewswire Inc.
- Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D FilingBenzinga
- Lifecore Biomedical: Bid Is UnderwhelmingSeekingAlpha
- Lifecore Biomedical to be Acquired by Webster Equity PartnersYahoo
We hide 2 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to LFCR’s 64, all within 1 point.
Sorted by closeness to LFCR’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.